BioMarin Pharma (BMRN) Tops Q2 EPS by 8c, Affirms FY Revenue Guidance, Lowers R&D Expense Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.39 --0%
EPS Growth %: +1,008.3%
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
OMID, ACI, UNH, More
EPS Growth %: +1,008.3%
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
OMID, ACI, UNH, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($0.09), $0.08 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $372.8 billion versus the consensus estimate of $3.62 billion.
GUIDANCE:
BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion.
BioMarin Pharma sees FY2018 R&D expense of of $645-685 million, prior was for $680-710 million
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
- Mizuho Upgrades Rexford Industrial Realty (REXR) to Outperform
- Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
